Study wrapper · #938
The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities.
Ganamurali N, Sabarathinam S Clinical pharmacology in drug development. 2026.
DOI: 10.1002/cpdd.70001PubMed: 41545327
Editor's note
This perspective frames retatrutide as a significant advance in obesity pharmacotherapy, citing Phase 2 weight reductions and potential metabolic benefits. It is an opinion-oriented review rather than new trial data, and its framing is notably promotional, so it should be read with caution about tone. Included for the retatrutide narrative.
Plain-language abstract
A perspective article describing retatrutide, a triple hormone-receptor agonist studied for obesity, and the Phase 2 weight-loss results reported to date.
Related coverage
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026
Supported
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
iSciencen=——2026
Supported
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
Canadian journal of physiology and pharmacologyn=——2026